Semaglutide medications including Ozempic and Wegovy have been shown to reduce kidney failure risk and the risk of death among people with kidney disease and type 2 diabetes. Two doctors weighed in.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to taking Ozempic: It may help manage chronic kidney disease (CKD). On ...

People often ask whether Ozempic helps them lose weight. Clinical trials have shown reductions in body weight among adults ...

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

Weekly injections of semaglutide medications like Ozempic significantly reduce the risk of serious kidney outcomes, major cardiovascular events and death among people who have type 2 diabetes and ...

Ozempic “can help those with co-conditions that have led to chronic kidney disease such as diabetes or other cardiovascular diseases,” says Dusty Price, A.P.R.N.-C.N.P., a certified nurse ...

The F.D.A. based its decision to expand the approved uses of Ozempic on research showing that people with Type 2 diabetes and chronic kidney disease who took the drug had a 24 percent lower ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S.

People taking Ozempic in a multinational trial experienced a 24 percent reduction in risk of death from cardiovascular and kidney disease compared with those who received a placebo.

Ozempic Cuts Risk of Chronic Kidney Disease Complications, Study Finds A major clinical trial showed such promising results that the drug’s maker halted it early. Listen to this article · 5:16 ...